Showing 4461-4470 of 7112 results for "".
- Santalis Pharmaceuticals Starts Phase 2 Study of New Sandalwood Oil-based AD Therapyhttps://practicaldermatology.com/news/australias-santalis-pharmaceuticals-starts-phase-2-study-of-new-ad-therapy/2458445/Santalis Pharmaceuticals has enrolled the first patient in a Phase 2 Study of 5% East Indian Sandalwood Oil (EISO) cream for the treatment of atopic dermatitis (AD). Up to 60 patients aged 3 months to 65 with a clinically stable diagnosis of AD who have a total body surface
- FDA Approves Enbrel Biosimilarhttps://practicaldermatology.com/news/fda-approves-enbrel-biosimilar/2458451/The U.S. Food and Drug Administration (FDA) approved Erelzi for multiple inflammatory diseases. Erelzi is a biosimilar to Enbrel (etanercept), which was originally licensed in 1998. The move is no surprise given the unanimous backing of an FDA advisory arm last month. There are now
- Kybella for Men May Mean Buh-Bye Beardshttps://practicaldermatology.com/news/kybella-for-men-may-mean-buh-bye-beards/2458456/If Allergan’s double-chin melting injectable Kybella were to really take off among men, we may be seeing a lot fewer beards, jokes bearded Washington DC –based dermatologist Terrence Keaney, MD. Male aesthetics is a growing market,
- It's So Far, So Good for BioPharmX's New Acne Drughttps://practicaldermatology.com/news/its-so-far-so-good-for-biopharmxs-new-acne-drug/2458458/BioPharmX Corporation’s novel topical minocycline, BPX-01, reduced facial P. acnes by more than 90 percent after four weeks, new research shows. In the Phase 2a study, a daily 10 mg dose of topical minocycline offered P. acnes r
- 23andMe Data Helps ID BCC Risk Geneshttps://practicaldermatology.com/news/23andme-data-helps-id-bcc-risk-genes/2458459/New research out of 23andMe and Stanford University School of Medicine pinpoints 31 genetic associations for basal cell carcinoma (BCC), 14 of which are all new. Taken together, these associations are estimated to explain almost 11 percent of the genetic risk for BCC, according to t
- Billionaire John Paul DeJoria Bets Big on Aubío for Cold Sores and Maybe Morehttps://practicaldermatology.com/news/billionaire-john-paul-digorio-bets-on-aubo-for-cold-sores-and-maybe-more/2458461/Billionaire John Paul DiJoria of Paul Mitchell Professional Hair Care Products and Patron Tequila fame is putting his money where his mouth is --- literally. DeJoria is now investing “heavily” in a new natural and sustainably produced over-the-counter (OTC) col
- Face-Aging App May Encourage Sun-Safe Behaviorhttps://practicaldermatology.com/news/face-aging-app-may-encourage-sun-safe-behavior/2458460/Appealing to their vanity may be the best way to encourage young women to practice sun-safe behaviors, a new study shows. The new research, published in
- Most Indoor Tanners Not in Favor of #Banthetan Movementhttps://practicaldermatology.com/news/most-indoor-tanners-not-in-favor-of-banthetan-movement/2458464/Most young adult women who regularly visit indoor tanning salons do support the introduction of policies to make it safer, but are against a total ban. The new findings appear in Translational Behavior
- Men, New Technologies Drive Growth in Body Contouring Markethttps://practicaldermatology.com/news/men-new-technologies-drive-growth-in-body-contouring-market/2458467/The body contouring market is set to rise from $671.8 million in 2015 to more than $1.1 billion by 2022, representing a compound annual growth rate of 7.9%, according to research and consulting firm
- Study: Some Black Teens Pulled Between Health and Hairhttps://practicaldermatology.com/news/study-some-black-teens-pulled-between-health-and-hair/2458468/Some girls and women in the black community feel as if they have to choose between their health and their hair, and this may play a role in the high rates of obesity seen in this population, new research shows. Susan Woolford, M.D., MPH, , a pediatrician at the University